Echinulin
Based on 1 Customer Validation
Echinulin (Echinuline) is a cyclic dipeptide carrying a triprenylated indole moiety. Echinulin contributes to the activation of T cell subsets, which leads to NF-κB activation.Echinulin exerts its immune roles by the NF-κB pathway.Echinulin has the potential to serve as a immunotherapeutic agent.
For research use only. We do not sell to patients.
- Purity : 98.63%
- CAS No.: 1859-87-6
- Formula: C29H39N3O2
- Molecular Weight:461.64
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
Description
IC50 & Target
[1]|
NF-κB |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| B16-4A5 | IC50 |
68 μM
Compound: 2
|
Inhibition of melanogenesis in theophylline-stimulated mouse B16-4A5 cells assessed as reduction in melanin level incubated for 72 hrs
Inhibition of melanogenesis in theophylline-stimulated mouse B16-4A5 cells assessed as reduction in melanin level incubated for 72 hrs
|
[PMID: 27641468] |
| BV-2 | IC50 |
>50 μM
Compound: 26
|
Inhibition of iNOS-mediated NO production in LPS-induced mouse BV2 cells
Inhibition of iNOS-mediated NO production in LPS-induced mouse BV2 cells
|
[PMID: 18926710] |
| MDCK | CC50 |
>200 μM
Compound: 22
|
Cytotoxicity against MDCK cells assessed as cell growth after 40 hrs by CellTiter-Glo assay
Cytotoxicity against MDCK cells assessed as cell growth after 40 hrs by CellTiter-Glo assay
|
[PMID: 25681711] |
Chemical Information
-
CAS No. 1859-87-6
-
Appearance Solid
-
Molecular Weight 461.64
-
Formula C29H39N3O2
-
Color White to off-white
-
SMILES
C/C(C)=C\CC1=C2C(C(C[C@H]3C(N[C@H](C(N3)=O)C)=O)=C(C(C)(C)C=C)N2)=CC(C/C=C(C)\C)=C1
-
Synonyms
Echinuline
-
Structure Classification
-
Initial Source
Aspergillus chevalieri
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Protocols
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Research Protocol for Cancer Immunology
Cancer immunology studies how the immune system recognizes, suppresses, edits, or fails to eliminate malignant cells through tumor antigen release, antigen presentation, T-cell priming, immune trafficking, tumor-cell killing, and feedback inhibition in the tumor microenvironment. The cancer-immunity cycle links tumor antigenicity, dendritic-cell priming, CD8+ T-cell infiltration, cytotoxic function, and immune-checkpoint regulation to tumor rejection or immune escape. Immune-checkpoint pathways such as PD-1/PD-L1 and CTLA-4 suppress antitumor T-cell activity and can be therapeutically blocked, but many tumors remain resistant because of poor antigen presentation, weak T-cell infiltration, suppressive myeloid cells, regulatory T cells, and tumor-intrinsic immune-exclusion programs. Unresolved questions include which immune-cell states predict response, how tumor-intrinsic pathways exclude immune cells, how myeloid suppression limits checkpoint blockade, and which combination strategies
Purity & Documentation
-
Data Sheet (270 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)